

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 December 2003 (18.12.2003)

PCT

(10) International Publication Number  
WO 03/104459 A1

(51) International Patent Classification<sup>7</sup>: C12N 15/12,  
A61K 67/00

(74) Agent: **BLAKE DAWSON WALDRON PATENT SERVICES**; Level 39, 101 Collins Street, Melbourne, Victoria 3000 (AU).

(21) International Application Number: PCT/AU03/00718

(22) International Filing Date: 6 June 2003 (06.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PS 2856 7 June 2002 (07.06.2002) AU  
2002950529 1 August 2002 (01.08.2002) AU

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*):  
**ARTHRON LIMITED** [AU/AU]; C/- Prima Biomed Limited, Unit 7, 79 - 81 High Street, Kew, Victoria 3101 (AU).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **HOGARTH, Phillip, Mark** [AU/AU]; 6 Robertson Street, Williamstown, Victoria 3016 (AU). **MOTTRAM, Patricia, Lesley** [AU/AU]; 76 Barkly Street, St Kilda, Victoria 3182 (AU). **SARDJONO, Caroline, Tan** [ID/AU]; 2/15 Powlett Street, Heidelberg, Victoria 3084 (AU).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/104459 A1

(54) Title: FCYRIIA TRANSGENIC ANIMAL MODEL FOR AUTOIMMUNE DISEASE

(57) Abstract: The present invention provides a FcγRIIa transgenic non-human animal model for autoimmune disease, particularly arthritis. This invention also provides a method of using this model to screen compounds that can reduce aberrant immune activity including aberrant immune complex formation aberrant immune complex clearance and immune complex induced inflammation. This invention also provides means of using this model to treat or prevent autoimmune disease.

**THIS PAGE IS BLANK**

14/PRTS

**FcγRIIa TRANSGENIC ANIMAL MODEL FOR  
AUTOIMMUNE DISEASE**

5

**Field of the Invention:**

10       The present invention relates to a non-human transgenic animal model for  
autoimmune disease, particularly arthritis. The invention also relates to methods for  
identifying compounds that can reduce aberrant immune activity and immune  
complex associated inflammation. This invention also relates to methods for  
identifying a mode of autoimmune disease development and for the identification of  
15       compounds that ameliorate this and the processes associated with this that lead to  
disease.

**Background of the Invention:**

20       Receptors for the Fc domain of IgG (FcγRs) amongst other factors are known to  
play a role in the regulation of the immune system. Currently, three classes of FcγRs  
are distinguished on cells of the immune system: the high-affinity receptor FcγRI  
(CD64), capable of binding monomeric IgG; the low-affinity receptors FcγRII (CD32)  
and FcγRIII (CD16), which interact preferentially with complexed IgG. Although these  
25       receptors show overlapping binding patterns for IgG subclasses, they vary in their  
cellular effector functions. FcγRI, FcγRIIa and FcγRIIIa are activating receptors,  
characterised by the presence of an immunoreceptor tyrosine-based activation motif  
immunoreceptor tyrosine-based activation motif (ITAM), either in the cytoplasmic  
domain of the receptor (FcγRIIa) or associated with the receptor as an accessory  
30       signalling subunit (γ and/or β chains associated with FcγRI and FcγRIIIa). By contrast,  
FcγRIIb is an inhibitory receptor, containing an immunoreceptor tyrosine-based  
inhibitory motif (ITIM) in its cytoplasmic domain. A marked exception to this  
dichotomy is FcγRIIIb; this receptor is linked to the outer leaflet of the plasma  
membrane by a glycosyl phosphatidylinositol (GPI) anchor and does not contain or  
35       associate with ITAMs or ITIMs. There is presently no homolog described for FcγRIIa  
or FcγRIIIb in mice.

Whilst FcR:Ig interactions are important effector systems in immunity, their  
role in autoimmune disease is uncertain. In humans the major inflammatory cells -  
macrophages, neutrophils, eosinophils and mast cells are known to express FcR

5 receptors, including FcγRI, FcγRIIa, FcγRIIb, and FcγRIIIa, or FcγRIIIb.

FcγRIIa is present only in humans and higher primates, so there is no equivalent in mice or other rodents. The receptor is of particular interest because of the dependence of other Fc receptors on this receptor for their signal transduction and cell activating properties (Chuang et al. 2000). FcγRIIa can be expressed in transgenic  
10 mice with the same expression pattern as in humans (McKenzie et al. 1999). Thus human FcγRIIa can interact appropriately with intracellular signalling pathways in the mouse and appear normal in all respects, although changes in cross-species regulation in transgenics should always be considered in interpreting results. Transgenic mice expressing the human FcγRIIa have shown that this receptor is a major factor in  
15 platelet destruction in immune thrombocytopenia (McKenzie et al. 1999). The role of FcR receptors in inducing cell activation is known for *in vitro* systems, but their role in inflammation *in vivo* is less understood and has recently been studied, as described herein.

As a result of the use of gene knock out animals, the scientific and medical  
20 communities believe that the principal receptor involved in the induction of inflammation *in vivo* is FcγRIII (also known as CD16). Many studies in the literature indicate this and this has formed part of recent text book descriptions of immune complex induced inflammation. It was therefore very surprising that transgenic mice expressing the human FcγRIIa are highly sensitive to immune complex induced  
25 inflammation, also spontaneously develop inflammation in a variety of organs and tissues characteristic of a number of autoimmune diseases such as rheumatoid arthritis, systemic lupus erthemotosus (SLE), induced autoimmune disease such as glomerular basement membrane nephritis. Moreover, mice that develop these surprising inflammatory sensitivities are also useful for testing drugs.

30 However, no studies have examined the role of this FcR in autoimmune disease, such as SLE, arthritis or any other immune complex disorders, for example, the role of this Fc receptor in immune complex or antibody induced inflammation associated with autoimmune diseases. Inflammation in these diseases can include vasculitis, lupus nephritis and arthritis. Inflammation can also occur in diseases not  
35 necessarily classified as autoimmune such as infectious arthritis, in renal diseases such as mixed cryoglobulinemia, bacterial infections, in malignant diseases, in gastrointestinal diseases, complement deficiencies and in a number of miscellaneous conditions.

Accordingly, there remains a need for providing effective methods and models

5 for autoimmune disease and methods for identifying compounds that can reduce aberrant immune activity, inflammation and disease processes. The surprising observation of the increased sensitivity to collagen induced arthritis in the transgenic mice whose genetic make up is composed of genes from otherwise genetically resistant mice, together with the observation of a spontaneous autoimmune disease, including arthritis was surprising. More surprising was that on further analysis of the transgenic animals, evidence of spontaneous autoimmunity and inflammation in tissues was evident. Inflammation in kidneys and in lungs occurred in many, though not all mice and histological examination of the joints showed features characteristic of rheumatoid arthritis, i.e. bone destruction and panus formation or features more characteristic of arthritis associated with diseases such as SLE where panus does not form. It would appear therefore that the presence of human FcγRIIa receptor in these mice allows the development of quite different inflammatory processes in different tissues that make up different clinical diagnoses.

20 **Summary of the Invention:**

A first aspect of the present invention is a method for screening a compound that is able to suppress aberrant immune activity, the method comprising the steps of:

- 25 (a) administering a compound to be screened to a non-human transgenic animal that has been modified to express human FcγRIIa receptor such that the transgenic animal is susceptible to an autoimmune disease; and  
(b) assessing the transgenic animal to determine if the compound reduces aberrant immune activity in the animal.

30 Preferably, the compound can reduce aberrant immune activity, such as but not limited to, aberrant immune complex formation, aberrant immune complex clearance or immune complex induced inflammation in a subject. The method of the present invention preferably includes the additional step of

- (c) assessing the transgenic animal to determine if the compound reduces immune complex induced inflammation.

35 A preferred aspect of the present invention is a method for screening a compound that is able to suppress an autoimmune disease, the method comprising the steps of:

5 (a) administering a compound to be screened to a non-human transgenic animal that has been modified to express human FcγRIIa receptor such that the transgenic animal is susceptible to an autoimmune disease; and

(b) assessing the transgenic animal to determine if the compound reduces aberrant immune activity in the animal.

10 The non-human transgenic animal is preferably resistant to collagen-induced arthritis prior to being modified to express the human FcγRIIa receptor. Preferably, the transgenic animal is a transgenic mouse derived from the strains C57BL/6 and SJL that has been modified to express human FcγRIIa receptor. The aberrant immune activity preferably includes aberrant immune complex formation, aberrant immune  
15 complex clearance or immune complex induced inflammation. Preferably, the compound is able to reduce aberrant immune activity in the animal by inhibiting the activity of FcγRIIa expressed in the animal. In step (b) of the method, the aberrant immune activity can be preferably assessed in terms of clinical symptoms and/or pathological features of an autoimmune disease, such as arthritis or systemic lupus  
20 erthematosus (SLE). Preferably, the autoimmune disease is an autoimmune disease other than thrombocytopenia. Preferably, the autoimmune disease may include systemic lupus erthematosus (SLE), Crohn's disease, mixed cryoglobulinemia and other conditions involving pathology due to immune complexes. More preferably, the autoimmune disease is rheumatoid arthritis (RA) or more preferably collagen-induced  
25 arthritis (CIA). The assessment step (b) may include suitable assays for assessing aberrant immune activity, such as a suitable antibody assay. Other assays include analysis of cytokine expression by immunohistochemistry, PCR or ELISA in situ or in circulation, immune function tests such as antigen presentation, biochemical tests such as cell signalling.

30 Another aspect of the present invention is a method for screening a compound that is able to suppress an autoimmune disease, the method comprising the steps of:

(a) administering a compound to be screened to a non-human cell expressing human FcγRIIa receptor, wherein the cell is derived from a non-human transgenic animal that has been modified to express human FcγRIIa receptor such that  
35 the transgenic animal is susceptible to an autoimmune disease; and

(b) assessing the cell to determine if the compound reduces aberrant immune activity in the cell.

The non-human transgenic animal is preferably resistant to collagen-induced arthritis prior to being modified to express the human FcγRIIa receptor. Preferably,

5 the transgenic animal is a transgenic mouse derived from the strains C57BL/6 and SJL that has been modified to express human FcγRIIa receptor. Preferably, the aberrant immune activity includes aberrant immune complex formation, aberrant immune complex clearance or immune complex induced inflammation. The compound is preferably able to reduce aberrant immune activity in the cell by inhibiting the activity of FcγRIIa expressed in the cell. The assessment step (b) may include suitable assays for assessing aberrant immune activity, such as suitable antibody assays. Other suitable assays include analysis of cytokine expression by immunohistochemistry chemistry, PCR or ELISA in situ or in circulation, immune function tests such as antigen presentation, biochemical tests such as cell signalling.

15 A further aspect of the present invention is a compound when identified by the screening methods of the present invention that can reduce aberrant immune activity in a cell or animal.

The invention also provides a method of treating or preventing an autoimmune disease in a subject, the method comprising administering an effective amount of a compound that can reduce aberrant immune activity in the subject.

20 Preferably, the compound can reduce aberrant immune complex formation, aberrant immune complex clearance or immune complex induced inflammation in a subject. Preferably, the compound is able to reduce aberrant immune activity in the cell by inhibiting the activity of FcγRIIa expressed in the subject. The compound used in the method is preferably identified by the screening methods of the present invention. Preferably, the autoimmune disease is caused by aberrant immune complex formation, aberrant immune complex clearance or immune complex induced inflammation. The autoimmune disease is preferably arthritis or systemic lupus erythematosus (SLE). Preferably, the autoimmune disease is rheumatoid arthritis (RA) or more preferably collagen-induced arthritis (CIA).

30 The present invention also provides a composition for treating or preventing an autoimmune disease, the composition comprising an effective amount of a compound that can reduce aberrant immune activity in an animal, and a pharmaceutically acceptable diluent, excipient or carrier.

35 Preferably, the compound in the composition is identified by the screening methods of the present invention. The autoimmune disease is preferably arthritis or systemic lupus erythematosus (SLE). Preferably, the autoimmune disease is rheumatoid arthritis (RA) or more preferably collagen-induced arthritis (CIA).

Another aspect of the present invention is a non-human transgenic animal that

5 has been modified to express human FcγRIIa receptor such that the transgenic animal is susceptible to an autoimmune disease, wherein the transgenic animal is resistant to collagen-induced arthritis prior to being modified to express the human FcγRIIa receptor.

10 The transgenic animal is preferably a mammal, such as, but not limited to, a rodent, dog, cat, pig, rabbit or non-human primate. More preferably, the transgenic animal is a mouse. More preferably, the transgenic animal is a transgenic mouse derived from the strains C57BL/6 and SJL that has been modified to express human FcγRIIa receptor. Preferably, the autoimmune disease is caused by aberrant immune complex formation, aberrant immune complex clearance or immune complex induced  
15 inflammation. The autoimmune disease is preferably arthritis or systemic lupus erythematosus (SLE). Preferably, the autoimmune disease is rheumatoid arthritis (RA) or more preferably collagen-induced arthritis (CIA).

In a preferred aspect of the invention the non-human transgenic animal as hereinbefore described is used in a method to identify a molecule associated with  
20 FcγRIIa ligand binding or a molecule dependent on FcγRIIa ligand binding. Preferably, the non-human transgenic animal is used in a method to identify a molecule including, but not limited to, antagonists or agonists of a ligand of FcγRIIa.

The present invention further provides a method of producing a non-human transgenic animal model for autoimmune disease, the method comprising the steps of:

25 (a) introducing a nucleic acid molecule encoding human FcγRIIa receptor to a cell of a non-human embryo;

(b) transferring the embryo to a foster mother; and

(c) assessing the resultant born animal for susceptibility to autoimmune disease;

30 wherein the non-human transgenic embryo is resistant to collagen-induced arthritis prior to the introduction of a nucleic acid molecule encoding a human FcγRIIa receptor.

The transgenic animal is preferably a mouse. More preferably, the transgenic animal is a transgenic mouse derived from the strains C57BL/6 and SJL that has been  
35 modified to express human FcγRIIa receptor. Preferably, the autoimmune disease is caused by aberrant immune complex formation, immune complex clearance or immune complex induced inflammation. The autoimmune disease is preferably arthritis or systemic lupus erythematosus (SLE). Preferably, the autoimmune disease is rheumatoid arthritis (RA) or more preferably collagen-induced arthritis (CIA).



5           The invention also provides a method for producing a composition for treating or preventing an autoimmune disease, the method comprising

- (a) selecting the compound by the method as hereinbefore described; and
- (b) formulating the compound with a pharmaceutically acceptable diluent, excipient or carrier to produce the composition.

10

**Brief Description of the Accompanying Figures:**

          Figure 1A shows feet of a mouse with typical spontaneous arthritis at >30 weeks. Features include swelling, redness and rigidity of the joints, compared with  
15       feet of a normal mouse as shown in Figure 1(B).

          Figure 2 shows a mouse hind limb with spontaneous arthritis (2A) and a normal mouse hind limb (2D). Histological staining (H&E sections, 400x magnification) of the knee joints of the arthritic mouse are shown in 2B and 2C, compared with a normal knee joint from an aged matched non-transgenic mouse (2E),  
20       showing inflammation with synovium hyperplasia and infiltrated by cells in the arthritic joint (2B). In mice with spontaneous arthritis, pannus formation and cartilage destruction were seen (in 29% of mice at 20-40 weeks and 33% of mice at >40 weeks), with inflammatory infiltration of the cartilage (2B). Interestingly in the other mice with the spontaneous arthritis, histology showed synovitis with fewer inflammatory  
25       cells and no pannus formation more characteristic of arthritis associated with disease such as Systemic Lupus Erythematosus (Fig 2C). Figure 2F shows the % cumulative incidence of spontaneous arthritis at 20 and 40 weeks.

          Figure 3 shows that examination of the organs from >20 week old transgenic mice revealed symptoms of autoimmune disease, with some of the features commonly  
30       seen in rheumatoid arthritis or human Systemic Lupus Erythematosus (SLE) (Edworthy 2001). The abnormalities included: pneumonitis with perivascular inflammation (Fig. 3A compared with normal lungs 3B) in 60 -100% of mice (Fig. 3C) and glomerulopathy (Fig. 3D compared with a normal kidney, 3E) in 40-67% of older mice (Fig. 3F).

35       Figure 4 shows electron microscopy of the kidneys from an old transgenic mouse, at the junction of the uriniferous space (us) and a capillary (cap), revealing irregular floccular electron density intra basement membrane, representative of immune complex deposition and identical to that seen in human kidneys from end-stage SLE patients (Fig.4B). Intra-glomerular immune complex deposition in the

5 kidney of a mouse with glomerulopathy was also detected by fluorescein-conjugated anti-mouse IgG (Fig. 4C). This was a feature not seen in aged matched non-transgenic mice (Fig. 4D). High titres of anti-nuclear antibody were detected in the sera from 83% of transgenic mice aged >20 weeks, staining the cell nucleus with the "homogenous nuclear pattern" (Fig. 4E). The same pattern was observed with an anti-histone  
10 antibody (huPIA3) (Fig. 4F), indicating that at least one component of the anti-nuclear antibody detected in the transgenic mice was anti-histone. Anti-nuclear antibodies (ANA) with this staining pattern are found in 70-95% of SLE patients and are one of the indicators for SLE (Edworthy 2001). Unlike the other features of autoimmune disease, ANA was also detected at low levels in transgenic mice examined at 12 weeks,  
15 and in age matched non-transgenic controls. This parallels the human situation, where up to 30% of the population may have serum ANA with no symptoms of autoimmune disease. No antibodies for double stranded DNA were seen (data not shown). No lung or kidney disease was seen in age matched non-transgenic C57BL/6 or (C57BL/6 x SJL) F<sub>1</sub> mice.

20 **Figure 5 shows that DBA/1 mice (H-2<sup>a</sup>) immunised with collagen type 11 (CII) develops an arthritis. Collagen induced arthritis (CIA) disease development and severity in FcγRIIa transgenic mice (C57BL/6 and SJL genetic background) was compared with the CIA-resistant background strains (C57BL/6 (H-2<sup>b</sup>) and C57BL/6 x SJL F1 (H-2<sup>b/s</sup>)) with the susceptible DBA/1 (H-2<sup>a</sup>) mice. The FcγRIIa transgenic mice  
25 developed arthritis with more rapid onset (as early as day 20) and greater severity than in the susceptible DBA/1 mice. The non-susceptible strains did not develop arthritis. Fig. 5C: circles show CIA score in transgenic mice: squares show the score in DBA/1 mice, triangles show C57BL/6 mice. Histology of the joints from FcγRIIa, DBA/1, C57BL/6 and (C57BL/6 x SJL) F<sub>1</sub> mice culled on day 36 post arthritis  
30 induction confirmed this diagnosis. FcγRIIa transgenic mice showed massive synovial inflammation (Fig. 5A) and some articular erosion, caused by invading inflammatory cells replacing normal articular cartilage, and the development of pannus in the joint (Fig. 5B). These lesions were also found in the DBA/1 mice, but not in the joints from non-susceptible strains such as C57BL/6. Pannus formation progressing to  
35 degradation of the extracellular matrix, is a common feature of joints in humans with rheumatoid arthritis.**

**Figure 6 shows a graph indicating the incidence of spontaneous arthritis in FcγRIIa mice. The percentage % incidence at each time point is shown in grey and the**

5 cumulative prevalence % in mice (n=50) with disease is shown in black. Note that this is a much larger cohort of mice to those analysed in Fig. 2.

Figure 7 shows a graph of the level of arthritis index over time for CIA in mice (n=4) treated with only two doses of VIB 153 (7.5mg/dose on days 21 and 27), no treatment (n=28) or mice (n=15) treated with 4 doses of VIB 153 (7.5mg/dose on days 10 21, 24, 27, 30). CIA was induced by intradermal injection of an emulsion formed by combining 2 mg/ml chicken collagen type II (Sigma, St Louis, MO) dissolved in 10 mM acetic acid in an equal volume of CFA. 100 µl of the emulsion was injected i.d. into the base of the tail. The same dose was prepared and administered proximal to the primary site 21 days later (Campbell et al. 1997).

15 Figure 8 shows typical swelling, redness and rigidity of the ankle joints, in the feet of a transgenic mouse with CIA (A), in contrast to the normal appearance of the feet of (B) a treated transgenic mouse (4 doses of VIB 153, 7.5mg/dose on days 21, 24, 27, 30) at day 32.

Figure 9 shows a graph of level of arthritis index for CIA in non transgenic DBA/1 mice (n=12) treated with VIB 153 (4 doses, 7.5mg/dose on days 21, 24, 27, 30) 20 or untreated mice (n=27), clearly demonstrating that VIB 153 is not effective in treating CIA in non-transgenic mice.

Figure 10 and Figure 11 show graphs of level of arthritis (index or score) for individual mice treated after arthritis was established (4 doses, 7.5mg/dose on days 25 21, 24, 27, 30) with the following drug compounds: 6727, 6728, VIB197 and VIB 153. This demonstrated that the drugs are effective in treating established arthritis when disease index is low.

Figure 12 and Figure 13 show graphs of the level of arthritis (index or score) in mice with CIA treated with the following drug compounds prior to disease onset: 30 6727, 6728, VIB197, VIB 153 (4 doses, 7.5mg/dose on days 21, 24, 27, 30) or no treatment (n=6 mice/group).

Figure 14 shows a graph of the level of arthritis index in FcγR11a transgenic mice with CIA treated prior to disease onset with known immunosuppressive and nati-inflammatory agents anti-CD3 monoclonal antibody or methotrexate compared 35 with controls (PBS treated).

### **Detailed Description of the Invention:**

A first aspect of the present invention is a method for screening a compound

5 that is able to suppress aberrant immune activity, the method comprising the steps of:

(a) administering a compound to be screened to a non-human transgenic animal that has been modified to express human FcγRIIa receptor such that the transgenic animal is susceptible to an autoimmune disease; and

10 (b) assessing the transgenic animal to determine if the compound reduces aberrant immune activity in the animal.

Preferably, the compound can reduce aberrant immune activity, such as but not limited to, aberrant immune complex formation, aberrant immune complex clearance or immune complex induced inflammation in a subject. The method of the present invention preferably includes the additional step of:

15 (c) assessing the transgenic animal to determine if the compound reduces immune complex induced inflammation.

In a preferred aspect of the invention there is provided a method for screening a compound that is able to suppress an autoimmune disease, the method comprising the steps of:

20 (a) administering a compound to be screened to a non-human transgenic animal that has been modified to express human FcγRIIa receptor such that the transgenic animal is susceptible to an autoimmune disease; and

(b) assessing the transgenic animal to determine if the compound reduces aberrant immune activity in the animal.

25 In the present specification the term "autoimmune disease" is to be understood to include a heterogeneous group of disorders in which the recognition of self antigens by lymphocytes is involved in pathogenic organ damage (for example see tables 22-1, 22-2 and 12-2 of Edworthy (2001). Antibodies and immune complexes can also be involved in tissue damage in disease not strictly autoimmune in nature. The term  
30 therefore includes diseases or conditions that are caused by aberrant immune activity. The phrase "aberrant immune activity" refers to abnormal immune function in a cell, such as but not limited to, aberrant antibody or immune complex formation, aberrant antibody or immune complex clearance or immune complex induced inflammation. Preferably, the aberrant immune activity includes elevated immune complex  
35 formation in a cell compared to normal cells. The aberrant immune activity may preferably include elevated levels of antibodies or immune complex clearance in a cell compared to normal cells. The autoimmune disease is preferably caused by aberrant immune complex formation. (see Edworthy, 2001).

Aberrant immune complex formation is typically characterised by the presence

5 of soluble immune complexes, formation of complexes *in situ*, and the deposition of immune complexes in target organs. The autoimmune disease may be preferably caused by aberrant immune complex clearance. Aberrant immune complex clearance is typically characterised by the inability of phagocytes of the reticuloendothelial system to bind immune complexes via FcR. This can be due to abnormalities in or lack  
10 of phagocytic cells, aberrations of the FcR, or over-production of immune complexes due to uncontrolled anti-self antibody production.

The autoimmune disease is preferably arthritis or systemic lupus erythematosus (SLE). Preferably, the autoimmune disease is rheumatoid arthritis (RA) or more preferably collagen-induced arthritis (CIA). Other autoimmune diseases or  
15 inflammatory conditions associated with antibody or immune complex formation are listed in Table 12-2 of Edworthy (2001).

The non-human transgenic animal is preferably resistant to collagen-induced arthritis prior to being modified to express the human FcγRIIa receptor. Preferably, the transgenic animal is a transgenic mouse derived from the strains C57BL/6 and SJL  
20 that has been modified to express human FcγRIIa receptor. The aberrant immune activity preferably includes aberrant immune complex formation and/ or aberrant immune complex clearance. Preferably, the compound is able to reduce aberrant immune activity in the animal by inhibiting the activity of FcγRIIa expressed in the animal.

25 In step (b) of the method, the aberrant immune activity can be preferably assessed in terms of clinical symptoms and/or pathological features of an autoimmune disease, such as but not limited to arthritis or systemic lupus erythematosus (SLE). Preferably, the autoimmune disease is an autoimmune disease other than thrombocytopenia. Preferably, the autoimmune disease may include  
30 systemic lupus erythematosus (SLE), Crohn's disease, mixed cryoglobulinemia and other conditions involving pathology due to immune complexes. More preferably, the autoimmune disease is rheumatoid arthritis (RA) and most preferably collagen-induced arthritis (CIA). Clinical symptoms of an autoimmune disease or aberrant immune activity can include pathological cellular or tissue indicators that are  
35 recognised to be associated with autoimmune disease. For instance, the severity of an autoimmune disease such as arthritis may be assessed by the level of inflammation or swelling of a joint of an animal. Tissue samples of an animal may be assessed for damage characteristic of autoimmune diseases, such as arthritis. For example, histological examination of tissue sections can be carried out to identify damage such

5 as pannus formation, infiltration, cartilage and/or bone damage or erosion. Other indicators of inflammatory, or autoimmune disease, include leukocyte infiltration of target organs such as lungs, pancreas, salivary glands, lungs, bowel, skin, muscle, testes and eyes lesions. Intra glomerular immune complex deposition, associated with high titre anti-nuclear antibodies is detected by immunohistology and electron  
10 microscopy. Anti-nuclear antibodies, Rheumatoid factor and enzyme-specific antibodies (eg anti-insulin) can be detected in ELISA assays.

The assessment step (b) of the method of screening may include suitable assays for assessing aberrant immune activity, such as a suitable antibody assay. For instance, Systemic Lupus Erthematosus (SLE) is an autoimmune disease characterised  
15 by the development of antinuclear antibodies (ANA), especially against DNA. Therefore, antinuclear antibodies can be used to assay the level of ANAs in an animal to test for SLE. Other assays are listed in table 11-2 of Edworthy (2001). In an aspect of the present invention there is provided a method for screening a compound that is able to suppress an autoimmune disease, the method comprising the  
20 steps of:

- (a) administering a compound to be screened to a non-human cell expressing human FcγRIIa receptor, wherein the cell is derived from a non-human transgenic animal that has been modified to express human FcγRIIa receptor such that the transgenic animal is susceptible to an autoimmune disease; and  
25
- (b) assessing the cell to determine if the compound reduces aberrant immune activity in the cell.

The non-human transgenic animal is preferably resistant to collagen-induced arthritis prior to being modified to express the human FcγRIIa. Preferably, the transgenic animal is a transgenic mouse and more preferably of the C57BL/6 and  
30 genetic backgrounds that has been modified to express human FcγRIIa receptor. The mouse is characterised in the published paper by McKenzie et al. 1999, listed in references.

The aberrant immune activity preferably includes aberrant immune complex formation and/or aberrant immune complex clearance. The aberrant immune activity  
35 may be measured in a cell by preferably assessment in terms of clinical symptoms and/or pathological features of an autoimmune disease, such as arthritis or systemic lupus erythematosus (SLE). Preferably, the autoimmune disease is an autoimmune disease other than thrombocytopenia. Preferably, the autoimmune disease may include systemic lupus erthematosus (SLE), Crohn's disease, mixed cryoglobulinemia

5 and other conditions involving pathology due to immune complexes. More preferably, the autoimmune disease is rheumatoid arthritis (RA) and most preferably collagen-induced arthritis (CIA). Clinical symptoms of an autoimmune disease or aberrant immune activity can include pathological cellular or tissue indicators that are recognised to be associated with autoimmune disease. For instance, the severity of an  
10 autoimmune disease such as arthritis may be assessed by the level of inflammation or swelling of a joint of an animal. Tissue samples of an animal may be assessed for damage characteristic of autoimmune diseases, such as arthritis. For example, histological examination of tissue sections can be carried out to identify damage such as pannus formation, infiltration, cartilage and/or bone damage or erosion. Other  
15 indicators of inflammatory autoimmune or connective tissue disease, include leukocyte infiltration of target organs such as lungs, pancreas, salivary glands, lungs, bowel, skin, muscle, testes and eye lesions. Intra glomerular immune complex deposition, associated with high titre anti-nuclear antibodies is detected by immunohistology and electron microscopy. Anti-nuclear antibodies, anti-collagen  
20 antibodies and Rheumatoid factor can be detected in by FACS and ELISA assays. Aberrant cytokine secretion (TNF-alpha, IL1, in RA) can be detected by ELISA, ELISPOT or RNase protection assays. The assessment step (b) may include suitable assays for assessing aberrant immune activity, such as a suitable antibody assay. Anti-nuclear antibodies, anti-collagen antibodies and Rheumatoid factor can be detected in  
25 by FACS and ELISA assays.

The compound identified in the screening method of the present invention is preferably able to change aberrant immune activity in the cell by inhibiting the activity of FcγRIIa expressed in the cell. The compound may be an antagonist of FcγRIIa, such as an antibody against FcγRIIa or a soluble FcγRIIa protein fragment. Other suitable  
30 compounds that may be screened in the methods of the present invention may include naturally occurring compounds, such as but not limited to proteins and nucleic acid molecules, recombinant molecules or synthetic agents. The compound may be a Fc receptor modulating compound such as those described in US patent 6,355,683 and WO 00/15214, the contents of which are herein incorporated. The compounds could  
35 also include antibodies, peptides, non natural peptides composed of non natural amino acids or non-natural bonds or synthesised using non natural synthetic methods or small chemical entities including inorganic and organic compounds or combinations thereof.

A further aspect of the present invention is a compound when identified by the

5 screening methods of the present invention that can reduce aberrant immune activity in a cell or animal. Such compounds would be suitable as pharmaceutical agents in the treatment or prevention of autoimmune diseases. Moreover, the compounds identified by the methods of the present invention may be used in studies to further elucidate autoimmune disease.

10 The invention also provides a method of treating or preventing an autoimmune disease in a subject, the method comprising administering an effective amount of a compound that can reduce aberrant immune activity in the subject.

Preferably, the compound can reduce aberrant immune complex formation and/ or aberrant immune complex clearance in a subject. Preferably, the compound is  
15 able to reduce aberrant immune activity in the cell by inhibiting the activity of FcγRIIa expressed in the subject. The compound used in the method is preferably identified by the screening methods of the present invention. Preferably, the autoimmune disease is caused by aberrant immune complex formation and/ or aberrant immune complex clearance. The autoimmune disease is preferably arthritis or systemic lupus  
20 erythematosus (SLE). Preferably, the autoimmune disease is rheumatoid arthritis (RA) or more preferably collagen-induced arthritis (CIA).

In the method of the present invention, the term "effective amount" means a concentration of at least one compound sufficient to provide treatment or prevention of an autoimmune disease in a subject. The effective amount of a compound used in  
25 the methods of the present invention may vary depending on the subject and the type and level of autoimmune disease.

The subject treated by the methods of the invention may be selected from, but is not limited to, the group consisting of humans, sheep, cattle, horses, bovine, pigs, poultry, dogs and cats. The compound administered to a subject is preferably  
30 formulated as a pharmaceutical composition. The compound can be administered to humans and other animals orally, rectally, parentally (ie intravenously, intramuscularly, or sub-cutaneously), intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), transdermally, buccally, or as an oral or nasal spray. Preferably, the compound is administered by  
35 injection to a tissue site of an autoimmune disease, such as a joint. The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use. Solid dosage forms of the compounds for oral administration may



5 include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and / or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b)

10 binders such as, for example carboxymethylcellulose, alginates, gelatine, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds g)

15 wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

Accordingly, the present invention also provides a composition for treating or

20 preventing an autoimmune disease, the composition comprising an effective amount of a compound that can reduce aberrant immune activity in an animal, and a pharmaceutically acceptable diluent, excipient or carrier.

Preferably, the compound in the composition is identified by the screening methods of the present invention. The autoimmune disease is preferably arthritis or

25 systemic lupus erythematosus (SLE). Preferably, the autoimmune disease is rheumatoid arthritis (RA) or more preferably collagen-induced arthritis (CIA).

The compositions of the present invention may be formulated as solutions and emulsions. Suitable excipients, such as emulsifiers, surfactants, stabilisers, dyes, penetration enhancers and anti-oxidants may also be present in the compositions.

30 Suitable carriers that may be added in the compositions can include, water, salt solutions, alcohols, polyethylene glycols, gelatine, lactose, magnesium stearate and silicic acid. The compositions may include sterile and non-sterile aqueous solutions. The compositions are preferably in a soluble form and the compounds are preferably, diluted in a soluble sterile buffered saline or water solution. The compositions can

35 also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances that increase the viscosity of the suspension and may also contain stabilisers. The solutions may also contain buffers, diluents and other suitable additives. The compositions can include other adjunct components that are compatible with the activity of the compounds. The

5 compositions of the present invention may be formulated and used as foams, including emulsions, microemulsions, creams and jellies. The formulations of the above compositions described would be known to those skilled in the field of pharmacy.

10 The compositions may be in the form of solid dosage forms, such as tablets, drags, capsules, pills, and granules which can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of  
15 embedding compositions which can be used include polymeric substances and waxes.

If desired, and for more effective distribution, the compounds can be incorporated into slow release or targeted delivery systems such as polymer matrices, liposomes, and microspheres. The compounds can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients. Liquid dosage  
20 forms of the compounds for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol,  
25 benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the compositions of the present invention can also  
30 include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavouring, and perfuming agents. The composition of the present invention may be in dosage forms for topical administration of the compound, such as powders, sprays, ointments and inhalants. The compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives,  
35 buffers, or propellants which may be required to provide a pharmaceutical composition.

Another aspect of the present invention is a non-human transgenic animal that has been modified to express human FcγRIIIa receptor such that the transgenic animal is susceptible to an autoimmune disease, wherein the transgenic animal is resistant to

5 collagen-induced arthritis prior to being modified to express the human FcγRIIa receptor.

The transgenic animal is preferably a mouse. More preferably, the transgenic animal is a transgenic mouse derived from the strains C57BL/6 and SJL that has been modified to express human FcγRIIa receptor. Preferably, the autoimmune disease is  
10 caused by aberrant immune complex formation and/ or aberrant immune complex clearance. The autoimmune disease is preferably arthritis or systemic lupus erythematosus (SLE). Preferably, the autoimmune disease is rheumatoid arthritis (RA) or more preferably collagen-induced arthritis (CIA).

The present invention further provides a method of producing a non-human  
15 transgenic animal model for autoimmune disease, the method comprising the steps of:

(a) introducing a nucleic acid molecule encoding human FcγRIIa receptor to a cell of a non-human embryo;

(b) transferring the embryo to a foster mother; and

(c) assessing the resultant born animal for susceptibility to autoimmune  
20 disease;

wherein the non-human transgenic embryo is resistant to collagen-induced arthritis prior to the introduction of a nucleic acid molecule encoding a human FcγRIIa receptor.

The transgenic animal is preferably a mouse. More preferably, the transgenic  
25 animal is a transgenic mouse derived from the strains C57BL/6 and SJL that has been modified to express human FcγRIIa receptor. Preferably, the autoimmune disease is caused by aberrant immune complex formation and/ or immune complex clearance. The autoimmune disease is preferably arthritis or systemic lupus erythematosus (SLE). Preferably, the autoimmune disease is rheumatoid arthritis (RA) or more preferably  
30 collagen-induced arthritis (CIA). The mouse is characterised in the published paper by McKenzie et al. 1999.

Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion  
35 of any other element, integer or step, or group of elements, integers or steps.

The invention will hereinafter be described by way of the following non-limiting Figures and Examples.

5    **Example 1 – Methods for Using a Transgenic Mouse Model for Autoimmune Disease.**

**(a)    Transgenic Mice Expressing Human IgG Receptor FcγRIIa.**

10            In transgenic mouse models of the present invention the following mice strains were used DBA/1 (H-2<sup>a</sup>) males at 8-12 weeks old, C57BL/6 (H-2<sup>b</sup>) and (C57BL/6 x SJL) F<sub>1</sub> (H-2<sup>b/s</sup>) males or females at 8-15 weeks old, and transgenic mice expressing the FcγRIIa human transgene on platelets, neutrophils and macrophages at physiological levels, (as described in McKenzie et al. 1999). Transgenic males or females at 12-15  
15 weeks old were used in collagen-induced arthritis (CIA) experiments, and > 25 weeks old for the spontaneous autoimmune disease studies. All mice were bred and kept in clean conditions and were fed a standard diet and water *ad libitum*. The mouse is characterised in the published paper by McKenzie et al. 1999, listed in references.

20    **(b)    Collagen Type II Preparation.**

              Complete Freund's Adjuvant (CFA) was prepared by mixing 100 mg heat-killed *M. tuberculosis* H37 Ra (Difco Laboratories, Detroit, MI) ground in 20 ml Incomplete Freund's Adjuvant (Difco Laboratories, Detroit, MI). An emulsion was  
25 formed by combining 2 mg/ml chicken collagen type II (Sigma, St Louis, MO) dissolved in 10 mM acetic acid in an equal volume of CFA. 100 µl of the emulsion was injected i.d. into the base of the tail. The same dose was prepared and administered proximal to the primary site 21 days later (Campbell et al. 1997).

30    **(c)    Clinical Assessment of Arthritis.**

              Mice were examined 2-3 times per week from day 14 onwards. The severity of arthritis was rated on a scale from 0 to 3 for each extremity based on the swelling, redness, and the joint function. Score 0 = normal, 1 = mild swelling and/redness, 2=  
35 severe swelling and redness, 3 = severe swelling and redness accompanied by joint dysfunction. The score of each mouse was calculated for the four limbs (maximum total score of 12 for each mouse) (Campbell et al. 1997).

5     **(d)     Assay for the Anti-Nuclear Antibodies (ANAs).**

ANA tests were performed on Chinese Hamster Ovary (CHO) cells adhered to a Lab-Tek Chamber 8 well slide (Nunc, Naperville, IL) for 5 hours at 37°C. The cells then were fixed with 100% acetone for 5 min at room temperature, and washed  
10     2 times with PBS/0.5% BSA. The cells were then incubated with mouse serum or anti-histone antibody raised in mice (antibody HuPIA3; cell line name 410.9D6A3 (Cosgrove 1987)) at various dilutions for 30 min on ice, followed by sheep anti-mouse IgG (Fab' 2 fragment)-FITC (Silenus, Melbourne, Australia) for 30 min on ice in the dark. For the staining shown in Figure 4E serum was diluted 1:1000  
15     and Figure 4F anti-histone antibody in ascites was diluted 1:500.

**(e)     Histopathology Assessment.**

At the end of experiments, the mice were culled and the organs were  
20     collected. Kidneys, lungs, and various other tissues were fixed with 10% formalin/ PBS and embedded in paraffin. Sections (4-6µm) were stained with hematoxylin and eosin. To detect immune complex deposition, kidney sections were stained with sheep anti-mouse IgG (Fab' 2 fragment)-FITC (Silenus, Melbourne, Australia)

Joint tissues were decalcified before paraffin embedding with a solution  
25     containing 5% HCl, 3.5% acetic acid glacial, 95% ethanol, and 12.5% chloroform. Decalcification was considered complete when joints were bleached and flexible. Sections (4-6µm) were stained with hematoxylin and eosin and examined for histological changes associated with arthritis (pannus formation, infiltration, cartilage and bone damage).  
30

**(f)     Electron Microscopy Assessment.**

Samples of kidney were cut into 1-2 mm cubes using razor blades, and then fixed by immersion in fixative containing 2-8% paraformaldehyde, 2-5%  
35     glutaraldehyde in 0.15 M cacodylate buffer at pH 7.4. After fixation for a minimum of 6 hours at 4°C, tissues were rinsed in cacodylate buffer and post-fixed in 1% osmium tetroxide, in 0.15 M cacodylate buffer, pH 7.4 for 2 hours at room temperature. Samples were then washed in distilled water and dehydrated in 10% incremental concentrations of acetone prior to embedding in Procure-Araldite resin.

5 During the dehydration procedure, tissues were stained en-block using a solution of  
2% uranyl acetate in 70 % acetone. Ultra thin sections were cut on a cryostat using  
glass knives and stained with 5% uranyl acetate in aqueous solution for 30 minutes at  
room temperature, followed by Reynolds lead citrate for 10 minutes. Ultra thin  
10 sections were examined in a Philips 300 electron microscope at 60 KV. \* All reagents  
were from ProSciTech Australia.

(g) Antibody Detection.

Serum levels of total IgG and anti-collagen type II antibodies were assayed  
15 using ELISA using standard techniques. Briefly 96-well Serocluster "U" vinyl plates  
(Costar, Cambridge, MA) were coated over night at 4°C with 50 µl / well of 50µg / ml  
collagen type II in 10 mM acetic acid. The plates were blocked with 2% BSA in PBS  
for 1 hour at room temperature. Mouse test sera were serial diluted and added to  
each well. The antibody bound to the plates was then detected by secondary sheep  
20 anti-mouse IgG (Fab' 2fragment)-HRP (Amersham LIFESCIENCE,  
Buckinghamshire, England) and developed using ABTS (Boehringer Mannheim,  
Rockville, MD). The absorbance at 405 nm was measured by an ELISA microreader.

(h) Statistical Analysis.

25

Data expressed as mean +/- SEM were compared using Student's test.

**Example 2 – Results from a Spontaneous Arthritis (SA) Mouse Model.**

30 Spontaneous arthritis was observed in 47% of FcγRIIa transgenic mice at >20  
weeks of age, increasing to 58% of mice aged >40 weeks and manifesting as swelling  
and reddening of the footpads and stiffening of the digits, knees and ankles (Figure  
1A, compared with aged matched control, Figure 1B). Histological examination of the  
limbs confirmed the diagnosis of arthritis, shown in Figure 2B and 2C (compared with  
35 normal limbs from age matched non-transgenic mice (Figure 2E)) revealed  
inflammation with synovium hyperplasia and infiltration by polymorphonuclear cells.  
In most of the cases with spontaneous arthritis, pannus formation and cartilage  
destruction were seen, with inflammatory infiltration of the cartilage (Figure 2B).  
However, in about one third of mice with the spontaneous arthritis, histology showed

5 sub acute synovitis, less inflammatory cells and no pannus formation (Figure 2C). Figure 2F shows the % cumulative incidence of spontaneous arthritis at 20 and 40 weeks, with pannus formation in 29% at 20 weeks and 33% at >40 weeks.

Examination of the organs from these and other >20 week old transgenic mice revealed symptoms of autoimmune connective tissue disease, with some of  
10 the features commonly seen in human Systemic Lupus Erythematosus (SLE) (Edworthy 2001). The abnormalities included pneumonitis with perivascular inflammation in 60-100% of mice (Figure 3A, 3C) and glomerulopathy in 40-67% (Figure 3D, F). Intra-glomerular immune complex deposition in the latter was detected by fluorescein-conjugated anti-mouse IgG (Figure 4C); a feature not seen  
15 in aged matched non-transgenic mice (Figure 4D). Electron microscopy of the kidneys from old transgenic mice (Figure 4A) confirmed the immunohistochemistry, showing irregular floccular electron density intra basement membrane, representative of immune complex deposition and identical to that seen in human kidneys from end-stage SLE patients (Figure 4B). Despite  
20 extensive kidney damage in older mice, increased proteinuria was not detected in these mice compared with non-transgenic older mice (data not shown). However, the onset of proteinuria in some autoimmune glomerulonephritis animal models apparently does not correlate with the sequale of glomerulonephritis and renal failure (Clynes, Dumitru et al. 1998). No lung or kidney disease was seen in age  
25 matched non-transgenic C57BL/6 or (C57BL/6 x SJL)<sub>F1</sub> mice (Figure 3B and E) and none of the other organs examined (salivary gland, pancreas, gut, brain, heart, lymph nodes, spleen, skin eyes) showed abnormalities in either transgenic or non-transgenic mice.

Transgenic expression of activation-linked FcγRIIIa clearly alters immune  
30 function in mice, making them susceptible to spontaneous immune complex disease. The observation of multiple symptoms of spontaneous immune complex disease in these mice provides the first direct evidence of a key role for this receptor in the development of such tissue specific autoimmune disease.

The present results show that spontaneous immune complex associated  
35 disease, manifesting initially as arthritis, was seen in mice carrying the human FcγRIIIA gene. Non-transgenics on the same genetic background never developed disease at this age. These mice showed evidence of other immune complex mediated autoimmune reactivity, with high serum levels of anti-nuclear antibodies and immune complex deposition in the kidneys. Arthritis was characterised by

5 inflammation of the synovium, with synovium hyperplasia, edema, cellular infiltration, and neovascularisation, leading to the formation of finger-like projections over the cartilage. This feature (pannus) is unique to rheumatoid arthritis and leads to chondrocyte breakdown, cartilage erosion and, eventually, bone reabsorption. Inflammation is stimulated by macrophage secretion of IL-1 and TNF alpha, leading to nitrous oxide and collagenase secretion, and chondrocyte death. T cell mediated  
10 induction of autoantibodies includes rheumatoid factor (RF), against the Fc portion of IgG. This is mostly IgM and seen in 70-90% of RA patients. Other autoantibodies, to collagen type II (the major cartilage component) and to keratin, are specifically diagnostic but not seen in all patients. FcγRIIa transgenic mice with spontaneous  
15 arthritis, show most of the above features at >25 weeks of age, providing evidence for the first time that expression of this FcR is involved in disease development.

### **Example 3 – Assessment of Systemic Lupus Erythematosus (SLE).**

20 Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterised by the development of antinuclear antibodies (ANA), especially against DNA. Antibodies to red and white blood cell surface antigens also develop, leading to anemia, thrombocytopenia, leukopenia, endothelial cell damage and vasculitis. Nerve damage is also seen. Renal failure and ultimately multiple organ failure are the  
25 end result. Many of these symptoms were seen in the aging FcγRIIa mice in that they also develop glomerulonephritis, pneumonitis and anti-nuclear antibodies. No mice were positive for rheumatoid factor. Detection of anti-nuclear antibodies which are symptoms of SLE were assessed in the following manner.

High titres of anti-nuclear antibody were seen in 83% of the sera from transgenic mice  
30 aged >20 weeks, staining the cell nucleus with the "homogenous nuclear pattern". The same pattern was observed with an anti-histone antibody (huPIA3) (Figure 4E and 4F), indicating that the anti-nuclear antibody detected was anti-histone. Anti-nuclear antibodies with this staining pattern are found in 70-95% of SLE patients and are one of the indicators for SLE, although not diagnostic of the disease (Edworthy 2001).

35 Unlike the other features of autoimmune disease, ANA was also detected in transgenic mice examined at 12 weeks, and in age matched non-transgenic controls. This parallels the human situation, where up to 30% of the population may have serum ANA with no symptoms of autoimmune disease. No antibodies for double stranded DNA, were seen (data not shown).



- 5 A summary of symptoms and disease incidence is shown in Table 1. As mentioned above, ANA appeared before other indicators of autoimmune disease, but was not clearly associated with disease development, since it was also seen in older non-transgenic animals. Of the 23 transgenic mice examined at >20 weeks, 19 (83%) had other symptoms of connective tissue disease. Of the disease free mice, 3 were  
 10 aged 21-40 weeks and one was >40 weeks. Glomerulonephritis (Gn), with or without pneumonitis (Gn/Pn) was the most frequently observed disease: of 16 mice with these symptoms, 8 had Gn/Pn with no arthritis, 8 had arthritis and 5 of these had pannus. Gn severity increased with age but arthritis scores did not, with swelling and redness declining with time, although the joints remained stiff. Only one mouse (examined at  
 15 30 weeks) had all symptoms (ANA, Gn, arthritis, pannus). Three mice had arthritis only, and two of these showed pannus formation. Thus, these Gn/Pn and arthritis symptoms seem to develop independently. As expected, pannus development was dependent on arthritis (11 mice had arthritis: in 7 of these pannus was observed).

20 Table 1. Disease and Symptoms\* Summary

Normal mice								
C57Bl/6 (M)		age						
C57Bl/6xSJL		culled			Arthritis		Kidney	
(F1)	Sex	(weeks)	ANA	dsDNA	Score	Pannus	GN	Pneumonitis
M#1		25	-	-	0	-	-	-
M#2		25	+	-	0	-	-	-
M#old		>35	+	-	0	-	-	-
M#1a		32	-	-	0	-	-	-
M#2b		32	+	-	0	-	-	-
F1#1		>44	-	-	0	-		
F1#2		>44	-	-	0	-		
F1#3		>52	+	-	0	-		
Transgenic mice Group 1:								
<20 weeks	Sex	age culled (weeks)	ANA	dsDNA	Arthritis Score	Pannus	Kidney GN	Pneumonitis
S4.0.2	M	12	-	-	0	-	-	
S4.0.3	M	12	+	-	0	-	-	
S4.0.1	M	12	+	-	0	-	-	
S4.0.4	M	12	+	-	0	-	-	

Transgenic mice Group 2:							
21-40 weeks	Sex	age culled (weeks)	ANA	Arthritis Score	Pannus	Kidney GN	Pneumonitis
S3.9N.13	F	25		0	-	+++	+
S3.5.17	F	32	+	0	-	-	
S3.1.1	M	35	-	0	-	-	
S3.1.2	M	36	+	0	-	-	
S3.4.14	M	37	+	0	-	-/+	
S3.4.11	M	38	+	0	-	+	
S3.4.16	M	38	-	0	-	-/+	
S3.7.4	M	36		3	-	++	
S3.1.5	M	36	-	6	-	-	
S2.1		30	+	10	+	+++	
S8.0.3	F	31		10	+	+	-
ITP6.3		25	+	11	-	-	-
S8.0.2	F	32	+	12	+	+	+
S8.0.1	F	40	+	12	+	-	+
Transgenic mice GROUP 3:							
>40 weeks	Sex	age culled (weeks)	ANA	Arthritis Score	Pannus	Kidney GN	Pneumonitis
S3.2.8	F	52		0	-	++	
S3.6.76	F	52	+	0	-	+++	+
S7#2	F	54	+	0	-	+++	
S3.2.6	F	52	+	0	-	-	
S3.2.5	F	52		0	-	+++	
S7#1	F	47	+	4	-	-	
S7#3	F	54	+	5	+	-/+	
S7#4	F	54	+	10	+	++	
S3.2.7	F	52	+	10	+	-	+

5

ANA, pannus and pneumonitis results are presented as positive (+) or negative (-). Arthritis scores were calculated as described above (score from 0-12). Kidney disease was scored as absent (-), mild (-/+), moderate (++) or severe (+++).

5 ANA appeared before other indicators of autoimmune disease, but was not  
clearly associated with disease development, since it was also seen in older non-  
transgenic animals. Of the 23 transgenic mice examined at >20 weeks, 19 (83%) had  
other symptoms of disease. Of the disease free mice, 3 were aged 21-40 weeks and  
one was >40 weeks. Glomerulonephritis (Gn), with or without pneumonitis (Gn/Pn)  
10 was the most frequently observed disease: of 16 mice with these symptoms, 8 had  
Gn/Pn with no arthritis, 8 had arthritis and 5 of these had pannus. Gn severity  
increased with age but arthritis scores did not with swelling and redness declining  
with time, although the joints remained stiff. Only one mouse (examined at 30  
weeks) had all symptoms (ANA, Gn, arthritis, pannus). Three mice had arthritis  
15 only, and two of these showed pannus formation. Thus, these Gn/Pn and arthritis  
symptoms seem to develop independently. As expected, pannus development was  
dependent on arthritis (11 mice had arthritis- 7 of these pannus was observed).

#### **Example 4 - Results from a Collagen-Induced Arthritis (CIA) Mouse Model.**

20

CIA disease development and severity were compared in FcγRIIa transgenic  
mice with the CIA-resistant background strains (C57BL/6 H-2<sup>b</sup> and (C57BL/6 x  
SJL)F1, H-2<sup>b/s</sup>) and with the CIA susceptible DBA/1 (H-2<sup>k</sup>) mice. In contrast to the  
background strains, that did not develop CIA, the FcγRIIa transgenic mice developed  
25 arthritis with more rapid onset (as early as day 20) and greater severity than in  
DBA/1 mice (Figure 5C). Histology of the joints from FcγRIIa, DBA/1, C57BL/6 and  
(C57BL/6 x SJL)F1 mice culled on day 36 post arthritis induction confirmed this  
diagnosis. FcγRIIa transgenic mice showed massive synovial inflammation (Figure.  
5A) and some articular erosion, caused by invading inflammatory cells replacing  
30 normal articular cartilage, and the development of pannus in the joint (Figure. 5B).  
These lesions were also found in the DBA/1 mice, but not in the joints from  
non-susceptible strains such as C57BL/6. Pannus formation, due initially to the  
proliferation of fibroblast-like cells between articular surfaces, and progressing to  
degradation of the extracellular matrix, is a common feature of joints in humans with  
35 rheumatoid arthritis (Harris 2001). The results show that collagen-induced arthritis  
in FcγRIIa mice shows earlier onset and greater severity of disease than in DBA/1  
mice.

5    **Example 5 - Results of Anti-Collagen II Antibody and Rheumatoid Factor Detection.**

10    The titre of anti-collagen II antibody in the serum of transgenic, DBA/1 and C57BL/6 mice was measured by ELISA. Even though arthritis development was observed earlier in the FcγRIIa transgenic mice, they had lower antibody titres (detected at day 21 and day 36) than DBA/1 or C57BL/6 mice. These results suggest that inflammatory responses in the FcγRIIa transgenic mice are activated by low titre anti-collagen antibody, leading to rapid, early induction of arthritis. ELISA assays for antibodies to IgG, ie Rheumatoid factor (RF), gave no positive results. RF is normally  
15    not detected in mice with CIA.

**Example 6 - Results from the Spontaneous Arthritis (SA) Model.**

20    The transgenic mice used in this study expressed a uniquely human receptor for IgG, FcγRIIa, on the same cells and at physiological levels similar to that observed in humans. As they aged (>25 weeks) the mice developed spontaneous arthritis (SA), and showed abnormalities such as high titre anti-nuclear antibodies, inflammatory lung lesions and glomerulonephritis with intra-glomerular immune complex deposition. This study demonstrates a clear role for the human FcγRIIa in the  
25    development of immune complex disease in this mouse model system. Figure 6 shows the % incidence of new disease at each time point (grey) and the cumulative prevalence % of mice (n=50) with disease (black).

30    The findings demonstrate that spontaneous arthritis is attributable to the expression of human FcγRIIa. As shown in Figure 6, mice at 9-55 weeks of age were examined regularly for the development of arthritis.

35    Histological examination was performed on tissue samples (kidneys, lungs, and various other tissues) collected at 9-55 weeks of age and fixed with 10% formalin/ PBS and embedded in paraffin. Sections (4-6μm) were stained with hematoxylin and eosin. To detect immune complex deposition, kidney sections were stained with sheep anti-mouse IgG (Fab' 2 fragment)-FITC (Silenus, Melbourne, Australia). Joint tissues were decalcified before paraffin embedding with a solution containing 5% HCl, 3.5% acetic acid glacial, 95% ethanol, and 12.5 % chloroform. Decalcification was considered complete when joints were bleached and flexible. Sections (4-6μm) were stained with hematoxylin and eosin

- 5 (H&E) and diseased joints showed the histological changes characteristic of arthritis (pannus formation, infiltration, cartilage and bone damage). Figure 2 shows H&E stained sections of, (E): a normal knee joint and, (B): an arthritic knee joint from an SA mouse showing cartilage erosion and pannus formation.

10 **Example 7 - Collagen-Induced Arthritis in a Transgenic Mouse Strain Expressing Human FcγRIIa.**

In younger mice (8-12 weeks), the presence of the FcγRIIa gene in a mouse strain of mixed genetic background (C57BL/6/SJL, H-2<sup>b/s</sup>) that is normally resistant  
15 to collagen-induced arthritis (CIA), conferred susceptibility to this disease. Furthermore, these mice showed earlier onset of CIA than DBA/1 (H-2<sup>a</sup>) mice, a known susceptible strain (see below). CIA was induced in mice by i.d. injection of an emulsion of chicken collagen type II in Complete Freund's Adjuvant (CFA) into the base of the tail. Two injections were given, on day 0 and 21 of the experiment. The  
20 severity of arthritis was rated on a scale from 0 to 3 for each limb extremity based on swelling, redness, and the joint function.

- Score 0 = normal,
- 1 = mild swelling and/redness of footpads or digits,
- 2 = severe swelling and redness of footpads and digits,
- 25 • 3 = severe swelling and redness accompanied by joint dysfunction.

The score for each mouse was calculated by adding the scores of the four limbs (maximum score of 12 for each mouse) (Campbell et al. 1997).

The findings show that expression of the FcγRIIa transgene in mice results in disease susceptibility in a previously resistant strain, with greater disease severity and  
30 earlier onset than mice with a susceptible background. Thus the addition of FcγRIIa not only converted the CIA non-susceptible mice background into a susceptible strain, but also induced autoimmune disease closely resembling human rheumatoid arthritis and/or SLE in older mice, a disease not previously reported in the founding mouse strains (C57BL/6 or SJL). The results demonstrate that FcγRIIa plays an important  
35 role in the autoimmune disease development, in particular Rheumatoid Arthritis and SLE. Strategies that result in the blocking or down regulating of this receptor will also provide a promising therapeutic approach to inhibit autoimmune disease, such as Rheumatoid Arthritis and SLE, in humans.

### 5 **Example 8 - Testing of Compounds in Mice with Collagen-Induced Arthritis.**

10 In control mice (n=28), over a period of 37 days disease progressed and resulted in a mean score of 7.5 (Figure 7). No further increase in disease severity was seen from this time to > 60 days. Mice (n=15) treated with four 7.5mg doses of VIB 153 administered intra-peritoneally, commencing on day 21 (treated on day 21, 24, 27, 30), (Figure 7) and examined until >60 days, showed no disease until day 37 and only one mouse developed mild disease during this time. Mice treated with only two doses of VIB 153 (7.5mg/ dose on days 21 and 27) also showed very low levels of disease by day 37. Treated mice from the 4 dose group showed no signs of disease progression at > 60 days. In the untreated mice, the swelling decreased over time, but the paws remained stiff and immobile at >60 days. Again, diseased joints showed the histological changes associated with arthritis (pannus formation, infiltration, cartilage and bone damage), very similar to that seen with SA (see Figure 5). Figure 8 shows typical swelling and deformity in an untreated foot (A), in contrast to the normal appearance of the foot of a treated mouse (B) at day 32.

15 In a non-transgenic strain of mice that is susceptible to CIA (DBA/1) control mice (untreated) (n=27) were found to develop CIA over time, with a mean arthritis index of 7 at 37 days. Mice (n=12) treated with three 7.5mg doses of VIB 153 on days 21, 24 and 27 also developed CIA, and by day 37 the disease was of similar severity to that of the controls (see Figure 9), showing that this drug has no effect when the transgene is absent.

### 25 **Example 9 - Additional Testing of Compounds in a Collagen-Induced Arthritis Mouse Model.**

30 Mice with spontaneous arthritis at >30 weeks that were treated with three 7.5mg doses of VIB 153 on days 0, 7, 14 after arthritis was observed had decreased swelling and redness at the end of treatment (mean scores reduced to 4, compared with 6 for untreated controls) but progression to joint stiffness was not prevented. Individual variation in this group of mice (n=3) was considerable, caused by the severity of disease at time of treatment. Mice with higher scores were less amenable to treatment.

In mice with CIA, some developed disease prior to drug treatment (after the

- 5 first collagen injection). These were treated with the same doses of drug as disease-free mice. Again, individual variation in this group of mice (n=2 mice/drug) was considerable, and depended on the severity of disease at time of treatment. Mice with higher scores were less amenable to treatment (Figures 10 and 11).

- 10 CIA was induced in mice by i.d. injection of an emulsion of chicken collagen type II in Complete Freund's Adjuvant (CFA) into the base of the tail. Two injections were given, on day 0 and 21 of the experiment. The severity of arthritis was rated on a scale from 0 to 3 for each limb extremity based on swelling, redness, and the joint function.

Score 0 = normal,

- 15 1 = mild swelling and / redness of footpads or digits,  
2 = severe swelling and redness of footpads and digits,  
3 = severe swelling and redness accompanied by joint dysfunction.

The score for each mouse was calculated by adding the scores of the four limbs (maximum score of 12 for each mouse) (Campbell et al. 1997).

- 20 Mice were treated with four 7.5mg doses of drug administered intra-peritoneally, commencing on day 21 (treated on day 21, 24, 27, 30), and examined until >60 days (see Figure 12 and 13. In the untreated mice, the swelling decreased over time, but the paws remained stiff and immobile at >60 days. Again, diseased joints showed the histological changes associated with arthritis (pannus formation,  
25 infiltration, cartilage and bone damage), very similar to that seen with SA. All of the drugs tested ( 6727, 6728, VIB197, VIB 153) modified the development of CIA, either delaying the onset of disease or reduce severity significantly, with low scores maintained for > 30 days.

- It is clear from these studies that the presence of FcRIIa confers sensitivity to  
30 immune complexes on these mice despite there being all the other activating and inhibitory Fc receptors – FcRI and FcRIII as well as FcRIIb – present in these mice. It would therefore be expected that in diseases other than autoimmune diseases such sensitivity to antibodies and inflammation caused by antibodies and immune complexes would be evident in FcγRIIa transgenic mice and would be useful for  
35 testing compounds to potentially treat these diseases.

## 5 Example 10 - Treatment of CIA with anti-T cell or anti-inflammatory agents

T cells are known to play a significant role in the induction of CIA. For instance, T cell inactivation with an anti-CD3 monoclonal antibody (KT3), that recognises the T cell receptor chain, before the onset of CIA in DBA/1 mice has been shown to reduce disease severity (Hughes, Wolos et al. 1994). In the present study anti-CD3 antibody was used at a dose that is known to be immunosuppressive in mice (Mottram, Murray-Segal et al. 2002), to treat FcγRIIa transgenic mice with induced CIA. CIA was induced in mice as described in Example 7, then the mice were treated on day 20, before disease onset and prior to the second collagen injection (day 21) and again on days 22, 23 and 25 with 0.5mg ip of anti-CD3. As reported for DBA/1 mice (Hughes, Wolos et al. 1994), this treatment delayed the onset of CIA, with the index remaining low in these mice until day 37 (Figure 14).

In the present study, treatment with methotrexate, a DMARD commonly used for the treatment of severe rheumatoid arthritis in humans (Hildner, Finotto et al. 1999), and known to be effective in delaying CIA in DBA/1 mice (Neurath, Hildner et al. 1999), was also effective in delaying CIA in the FcγRIIa transgenic mice (Figure 14). Methotrexate was used at a low dose for 14 days from the time of the second collagen injection (1mg/kg, ie 30g/30 gm mouse from day 21-35) (Figure 14). In both anti-CD3 and methotrexate treatment, arthritis was delayed due to depletion of inflammatory effector cells and disease increased in severity as immune function returned to normal after treatment ceased.

In contrast, treatment with anti-FcR agents (see above, examples 8 and 9) permanently halted disease progression, implying that essential initial steps in the inflammatory process were inhibited allowing disease prevention rather than delay. The data shown in Figure 14 demonstrates that known treatments, including biological agents such as monoclonal antibodies and drugs such as methotrexate, effective for CIA in DBA/1 mice, are equally effective in the FcγRIIa transgenic mice. CIA in the DBA/1 mice has been used as a test model for anti-arthritis drugs for many years (Phadke, Fouts et al. 1985; Imaizumi, Hinoue et al. 1991). The data of the present study demonstrates that the FcγRIIa transgenic mice also respond to treatments that are effective in DBA/1 mice and these mice can therefore be used to test anti-arthritis drugs.

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific



- 5   embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

- 10   All publications discussed above are incorporated herein in their entirety. Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in Australia or elsewhere before the priority date of each claim of this application.

5

**References:**

- Campbell, I. K., A. Bendele, et al. (1997). "Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice." *Ann Rheum Dis* 56(6): 364-8.
- 10 Chuang, F., Saroli, M. and Unkeless, J. (2000). "Convergence of Fc gamma receptor IIA and Fc gamma receptor IIB signalling pathways in human neutrophils." *J. Immunol.* 164(1): 350-60.
- Clynes, R., C. Dumitru, et al. (1998). "Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis." *Science* 279(5353): 1052-4.
- 15 Cosgrove, L. (1987). Monoclonal antibodies to platelet antigens. Department of Pathology. Melbourne, University of Melbourne.
- Edworthy, S. (2001). Clinical manifestations of Systemic Lupus Erythematosus. Kelley's Textbook of Rheumatology. S. Ruddy, E. Harris and B. Sledge. Philadelphia, Pennsylvania, W.B. Saunders Company. 2: 1105-1123.
- 20 Hildner, K., S. Finotto, et al. (1999). "Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis." *Clin Exp Immunol* 118(1): 137-46.
- Hughes, C., J. A. Wolos, et al. (1994). "Induction of T helper cell hyporesponsiveness in an experimental model of autoimmunity by using nonmitogenic anti-CD3 monoclonal antibody." *J Immunol* 153(7): 3319-25.
- 25 Imaizumi, K., H. Hinoue, et al. (1991). "Pathological evaluation of anti-rheumatic drugs on type II collagen-induced arthritis in DBA/1J mouse." *Jikken Dobutsu* 40(1): 95-9.
- McKenzie, S. E., S. M. Taylor, et al. (1999). "The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets: a transgenic mouse model." *J Immunol* 162(7): 4311-8.
- 30 Mottram, P. L., L. J. Murray-Segal, et al. (2002). "Remission and pancreas isograft survival in recent onset diabetic NOD mice after treatment with low-dose anti-CD3 monoclonal antibodies." *Transpl Immunol* 10(1): 63-72.
- 35 Neurath, M. F., K. Hildner, et al. (1999). "Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression." *Clin Exp Immunol* 115(1): 42-55.
- 40 Phadke, K., R. L. Fouts, et al. (1985). "Evaluation of the effects of various anti-arthritis drugs on type II collagen-induced mouse arthritis model." *Immunopharmacology* 10(1): 51-60.

5     Claims:

1.     A method for screening a compound that is able to suppress aberrant immune activity, the method comprising the steps of:
  - (a)     administering a compound to be screened to a non-human transgenic animal that has been modified to express human FcγRIIa receptor such that the transgenic animal is susceptible to an autoimmune disease; and
  - (b)     assessing the transgenic animal to determine if the compound reduces aberrant immune activity in the animal.
2.     A method for screening a compound that is able to suppress an autoimmune disease, the method comprising the steps of:
  - (a)     administering a compound to be screened to a non-human transgenic animal that has been modified to express human FcγRIIa receptor such that the transgenic animal is susceptible to an autoimmune disease; and
  - (b)     assessing the transgenic animal to determine if the compound reduces aberrant immune activity in the animal.
3.     A method for screening a compound that is able to suppress an autoimmune disease, the method comprising the steps of:
  - (a)     administering a compound to be screened to a non-human cell expressing human FcγRIIa receptor, wherein the cell is derived from a non-human transgenic animal that has been modified to express human FcγRIIa receptor such that the transgenic animal is susceptible to an autoimmune disease; and
  - (b)     assessing the cell to determine if the compound reduces aberrant immune activity in the cell.
4.     A method according to any one of claims 1 to 3, wherein the compound reduces aberrant immune activity selected from the group consisting of aberrant immune complex formation, aberrant immune complex clearance and immune complex induced inflammation.
5.     A method according to claim 1 or 2, wherein the method includes the additional step of:
  - (c)     assessing the transgenic animal to determine if the compound reduces immune complex induced inflammation.
6.     A method according to any one of claims 1 to 5, wherein the non-human transgenic animal is resistant to collagen-induced arthritis prior to being modified to express the human FcγRIIa receptor.

- 5 7. A method according to any one of claims 1 to 6, wherein the non-human transgenic animal is a transgenic mouse derived from the strains C57BL/6 and SJL that has been modified to express human FcγRIIa receptor.
8. A method according to any one of claims 1 to 7, wherein the compound reduces aberrant immune activity in the animal by inhibiting the activity of FcγRIIa  
10 expressed in the animal.
9. A method according to any one of claims 1, 2 and 4 to 8, wherein in step (b) the aberrant immune activity is assessed in terms of clinical symptoms and / or pathological features of an autoimmune disease.
10. A method according to any one of claims 1 to 9, wherein the autoimmune  
15 disease is selected from the group consisting of arthritis and systemic lupus erythematosus (SLE).
11. A method according to any one of claims 1 to 10, wherein the autoimmune disease is rheumatoid arthritis (RA).
12. A method according to any one of claims 1 to 10, wherein the autoimmune  
20 disease is collagen-induced arthritis (CIA).
13. A compound that can reduce aberrant immune activity in a cell or animal when identified by the method according to any one of claims 1 to 12.
14. A method of treating or preventing an autoimmune disease in a subject, the method comprising administering an effective amount of a compound that can reduce  
25 aberrant immune activity in the subject, wherein the compound is identified by the method according to any one of claims 1 to 12.
15. A method according to claim 14, wherein the compound can reduce aberrant immune complex formation, aberrant immune complex clearance or immune complex induced inflammation in a subject.
- 30 16. A method according to claim 14, wherein the compound can reduce aberrant immune activity in the cell by inhibiting the activity of FcγRIIa expressed in the subject.
17. A method according to any one of claims 14 to 16, wherein the autoimmune disease is caused by aberrant immune complex formation, aberrant immune complex  
35 clearance or immune complex induced inflammation.
18. A method according to any one of claims 14 to 17, wherein the autoimmune disease is selected from the group consisting of arthritis and systemic lupus erythematosus (SLE).

- 5 19. A method according to any one of claims 14 to 18, wherein the autoimmune disease is rheumatoid arthritis (RA).
20. A method according any one of claims 14 to 18, wherein the autoimmune disease is collagen-induced arthritis (CIA).
- 10 21. A composition for treating or preventing an autoimmune disease, the composition comprising an effective amount of a compound that can reduce aberrant immune activity in an animal, and a pharmaceutically acceptable diluent, excipient or carrier, wherein the compound is identified by the method according to any one of claims 1 to 12.
- 15 22. A composition according to claim 21, wherein the compound can reduce aberrant immune complex formation, aberrant immune complex clearance or immune complex induced inflammation in an animal.
23. A composition according to claim 21 or 22, wherein the compound can reduce aberrant immune activity in the animal by inhibiting the activity of FcγRIIa expressed in a cell of the animal.
- 20 24. A composition according to any one of claims 21 to 23, wherein the autoimmune disease is caused by aberrant immune complex formation, aberrant immune complex clearance or immune complex induced inflammation.
- 25 25. A composition according to any one of claims 21 to 24, wherein the autoimmune disease is selected from the group consisting of arthritis and systemic lupus erythematosus (SLE).
26. A composition according to any one of claims 21 to 25, wherein the autoimmune disease is rheumatoid arthritis (RA).
27. A composition according any one of claims 21 to 25, wherein the autoimmune disease is collagen-induced arthritis (CIA).
- 30 28. A non-human transgenic animal that has been modified to express human FcγRIIa receptor such that the transgenic animal is susceptible to an autoimmune disease, wherein the transgenic animal is resistant to collagen-induced arthritis prior to being modified to express the human FcγRIIa receptor.
- 35 29. A non-human transgenic animal according to claim 28, wherein the transgenic animal is a mouse.
30. A non-human transgenic animal according to claim 29, wherein the transgenic derived from the strains C57BL/6 and SJL that has been modified to express human FcγRIIa receptor.

- 5 31. A non-human transgenic animal according to any one of claims 28 to 30, wherein the autoimmune disease is caused by aberrant immune complex formation, aberrant immune complex clearance or immune complex induced inflammation.
32. A non-human transgenic animal according to any one of claims 28 to 31, wherein the autoimmune disease is selected from the group consisting of arthritis and
- 10 systemic lupus erythematosus (SLE).
33. A non-human transgenic animal according to any one of claims 28 to 32, wherein the autoimmune disease is rheumatoid arthritis (RA).
34. A non-human transgenic animal according to any one of claims 28 to 33, wherein the autoimmune disease is collagen-induced arthritis (CIA).
- 15 35. A method of producing a non-human transgenic animal model for autoimmune disease, the method comprising the steps of:
- (a) introducing a nucleic acid molecule encoding human FcγRIIa receptor to a cell of a non-human embryo;
  - (b) transferring the embryo to a foster mother; and
  - 20 (c) assessing the resultant born animal for susceptibility to autoimmune disease;
- wherein the non-human transgenic embryo is resistant to collagen-induced arthritis prior to the introduction of a nucleic acid molecule encoding a human FcγRIIa receptor.
- 25 36. A method according to claim 35, wherein the transgenic animal is a mouse.
37. A method according to claim 35 or 36, wherein the transgenic animal is a transgenic mouse derived from the strains C57BL/6 and SJL that has been modified to express human FcγRIIa receptor.
38. A method according to any one of claims 35 to 37, wherein the autoimmune
- 30 disease is caused by aberrant immune complex formation, immune complex clearance or immune complex induced inflammation.
39. A method according to any one of claims 35 to 38, wherein the autoimmune disease is selected from the group consisting of arthritis and systemic lupus erythematosus (SLE).
- 35 40. A method according to any one of claims 35 to 39, wherein the autoimmune disease is rheumatoid arthritis (RA).
- 41 A method according to any one of claims 35 to 39, wherein the autoimmune disease is collagen-induced arthritis (CIA).

- 5    42.    A method for producing a composition for treating or preventing an  
autoimmune disease, the method comprising
- (a)    selecting the compound by the method according to any one of claims 1  
         to 12; and
- (b)    formulating the compound with a pharmaceutically acceptable diluent,  
10    excipient or carrier to produce the composition.

**THIS PAGE IS BLANK**



**Figure 1A**




**Figure 1B**




DT09 Rec'd PCT/PTO 07 DEC 2004

**THIS PAGE IS BLANK**

**Figure 2**


DT09 Rec'd PCT/PTO 07 DEC 2004

**THIS PAGE IS BLANK**

**Figure 3**

DT09 Rec'd PCT/PTO 07 DEC 2004



**THIS PAGE IS BLANK**

**Figure 4**

DT09 Rec'd PCT/PTO 07 DEC 2004


THIS PAGE IS BLANK



**Figure 5****C**


DT09 Rec'd PCT/PTO 0.7 DEC 2004

**THIS PAGE IS BLANK**

**Figure 6**

DT09 Rec'd PCT/PTO 07 DEC 2004

**THIS PAGE IS BLANK**

**Figure 7**

DT09 Rec'd PCT/PTO 07 DEC 2004

**THIS PAGE IS BLANK**

Figure 8A




Figure 8B



DT09 Rec'd PCT/PTO 07 DEC 2004


**THIS PAGE IS BLANK**



**Figure 9**


DT09 Rec'd PCT/PTO 07 DEC 2004

**THIS PAGE IS BLANK**


**Figure 10**

DT09 Rec'd PCT/PTO 07 DEC 2004

**THIS PAGE IS BLANK**

**Figure 11**


**THIS PAGE IS BLANK**

**Figure 12**

DT09 Rec'd PCT/PTO 07 DEC 2004


**THIS PAGE IS BLANK**



**Figure 13**

DT09 Rec'd PCT/PTO 07 DEC 2004

**THIS PAGE IS BLANK**

**Figure 14**

DT09 R000 PCT/PTO 07 DEC 2004

**THIS PAGE IS BLANK**

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU03/00718

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
Int. Cl. 7: C12N 015/12; A61K 067/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols) SEE ELECTRONIC DATABASE BOX BELOW		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched SEE ELECTRONIC DATABASE BOX BELOW		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WPIDS CA MEDLINE: TRANSGEN?; FC; RECEPTOR; GAMMA.		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95/28959 A1 (SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH) 2 November 1995. See the entire document, in particular: the Abstract; page 44 lines 7 and 32; page 46 line 22; page 47 lines 14-25, page 51, lines 14-15; and page 52 line 21.	1-42
X	McKenzie SE et al (1999). The role of the human Fc receptor FcγRIIA in the immune clearance of platelets: a transgenic mouse model. The Journal of Immunology 162: 4311-4318. See the entire document.	1, 6, 8, 13, 14, 16, 21, 23, 28-34
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&amp;" document member of the same patent family</p>		
Date of the actual completion of the international search 4 July 2003		Date of mailing of the international search report 14 JUL 2003
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929		Authorized officer  PHILIPPA WYRDEMAN Telephone No : (02) 6283 2554

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/AU03/00718

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Kwack K et al (1995). Functional consequences of the interaction between T-cell antigen receptors and FcγRs on T cells. Immunology Letters 44: 130-143. See the entire document, in particular page 141.	1, 6, 8, 13, 14, 16, 21, 23, 28-34
X	WO 96/08512 A1 (AUSTIN RESEARCH INSTITUTE AND ANTI-INFLAMMATORY SYNDICATE NO. 1) 21 March 1996. See the entire document, in particular: page 32, lines 20-24; Figures 3 and 9-18; the Examples; and Claims 21 and 52.	13-27, 42

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU03/00718

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member			
WO	95/28959	AU	2461995		
WO	96/08512	CA	2198248	EP	0773960
				JP	10508463T

**THIS PAGE IS BLANK**